Clinical Trials
2
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2002
Completed
2
100.0%
No approval data available
- Imperagen secured £5 million in seed funding led by PXN Ventures to expand its quantum physics and AI-driven enzyme engineering platform, bringing total capital raised to £8.5 million. - The company's technology combines quantum-based simulations with AI models and automated robotics to predict and optimize enzyme mutations, moving beyond traditional trial-and-error methods. - Commercial applications have demonstrated significant productivity gains, with enzyme improvements of 677 times and 572 times achieved after five optimization cycles in partnership with a Fortune 500 personal care company. - The funding will support R&D expansion, laboratory scaling, AI team growth, and commercial development across pharmaceuticals, life sciences, personal care, and industrial biotechnology sectors over the next 18 months.
- Sonoma Biotherapeutics has appointed Stephen Dilly, MBBS, PhD, as its new President and CEO, replacing co-founder Jeff Bluestone who transitions to an advisory role. - The leadership change follows positive interim safety and efficacy results from the company's first-in-human study of SBT-77-7101 in patients with refractory rheumatoid arthritis. - Dr. Dilly brings nearly 40 years of biopharmaceutical experience and has been associated with the development, approval and launch of more than 25 marketed drugs. - The company is developing engineered regulatory T cell therapies for autoimmune and inflammatory diseases, with a collaboration pipeline including Regeneron.
